Senores Pharmaceuticals Ltd management interview: A Good Q2 For Senores Pharma | Revenue Growth To Stay Strong At 25-30% Minimum, Says Company
CNBC-TV18, 2026-11-02. Video: https://www.youtube.com/watch?v=xgvMr5-vv5g
- Revenue guidance: Management expects growth to continue in H2 and has guided for at least 25 to 30% minimum growth going forward, with revenue of ₹3,000 crore-plus in 3 to 4 years; it said the target could be reached sooner than anticipated.
- US subsidiaries: Amerisyn and Zoraya are expected to start operations this quarter. Amerisyn has about 12 ANDA launches planned before March 31st, 2027; the subsidiaries are expected to contribute more in FY28, support margins, and potentially add 1 to 2 more percentages to EBITDA as they scale.
- Product pipeline: The company expects 116 more products across its own and CDMO/CMO baskets, with about 160-odd products commercially launched in the US in 3 to 4 years. Management said the portfolio could grow 3, 3 and 1/2x in 3 years' timeframe, alongside 3,500-odd emerging-market registrations and more than 150 mid-tier-market products.
- US contribution: The US currently accounts for about 70% of revenue; management expects 2,000-odd crore of a ₹3,000 crore total to come from the US. It is evaluating acquisition opportunities to grow its US business and said it has mapped further growth beyond ₹3,000 crore.
- Apnar and emerging markets: Apnar recorded ₹22 crore sales last quarter, and management expects about ₹100 crore of revenue this year; it may be merged into Senores in another 6 months or so. Emerging-market EBITDA was 4% this quarter, with a full-year expectation of 15 to 20%.